Sensor Patch Market worth $23.91 billion by 2030
DELRAY BEACH, Fla., Sept. 6, 2025 /PRNewswire/ — The global sensor patch market is projected to grow from…
AAOS Updates Clinical Practice Guideline for the Management of Rotator Cuff Injuries
Updated guideline based on the latest evidence-based recommendations ROSEMONT, Ill., Aug. 28, 2025 /PRNewswire/ — The American Academy…
Leal Therapeutics Announces $30 Million Series A to Progress First-In-Class Neuro-Metabolic Therapies for Neurodegenerative and Neuropsychiatric Disorders with High-Unmet Need
Leal Therapeutics is developing first-in-class therapeutics to correct metabolic imbalances in the brain for treatment of high unmet…
Barti Raises $12M Series A to Accelerate AI-Powered EHR for Eye Care
SAN FRANCISCO, Aug. 25, 2025 /PRNewswire/ — Barti Software, a leading AI-powered company that provides innovative electronic health records…
ISS National Lab-Sponsored Experiment Tests 3D Bioprinted Tissue for Growing Artificial Livers
Researchers to evaluate how microgravity affects maturation of 3D bioprinted liver tissue to advance regenerative medicine in microgravity…
Ultima Genomics and Gene by Gene Partner to Expand Global Access to High-Quality, Low-Cost Sequencing on the UG 100™ Platform
Collaboration Extends Global Reach of High-Performance Genomic Sequencing on the UG 100™ Platform FREMONT, Calif. and HOUSTON, Aug.…
Novo Nordisk lowers cost of Ozempic® to $499 per month for self-paying patients, in support of patient access to authentic, FDA-approved semaglutide medicines
Ozempic® is the GLP-1 with the most FDA-approved uses for patients with type 2 diabetes including, improvement of…
Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
First Breakthrough Therapy Designation in the U.S. for SystImmune and Bristol Myers Squibb’s Izalontamab brengitecan (Iza-bren) based on data…